GeneOne Life Science Proposes 80% Reverse Stock Split to Cover Deficit, Amends Articles for Business Diversification – Management Turnaround Efforts Amid Shareholder Concerns

GeneOne Life Science will hold an extraordinary general meeting on June 11, 2026 to vote on an 80% reverse stock split (1:5 consolidation) to cover accumulated deficits, reducing outstanding shares from 90,882,907 to 18,176,581, with a record date of June 28.
The capital reduction aims to improve financial health by eliminating deficits, but while it does not affect intrinsic shareholder value, it signals underlying business weakness.
The company also proposes amending its articles of incorporation to expand business purposes into AI, EV parts, cosmetics, e-commerce, etc., and to align with revised commercial law regarding treasury stock and independent directors.
In the director election, Kim Kyung-jin replaces Lee Joon-kyu as a candidate, alongside Jeon Kyung-ha (current managing director) and Kim Hoon-bum (outside director candidate).
[AI Comprehensive Analysis]The reverse stock split is a necessary step for financial restructuring, but the massive share consolidation may be perceived as a sign of distress, likely weighing on short-term stock price. While business diversification efforts are positive, investment risk remains until performance improvement is visible.